Buy 3-MeO-PCE for sale online from USA vendor

Table of Contents

1. Introduction
2. Chemistry
3. Pharmacology
4. Subjective Effects
5. Dosage Guidelines
6. Physical Effects
7. Cognitive Effects
8. Toxicity and Harm Potential
9. Dangerous Interactions
10. Legal Status

Introduction

3-Methoxyeticyclidine (3-MeO-PCE), also referred to as Methoxieticyclidine, belongs to the arylcyclohexylamine class, known for its dissociative and hallucinogenic effects upon administration. Structurally, it is an analog of PCE, presenting unique pharmacological properties and effects.

Emergence and Popularity

The emergence of 3-MeO-PCE into the public sphere began around 2010 [2]. It swiftly gained traction within the online grey area research chemical market, marketed as a legal alternative to substances like PCP or ketamine [3][4][5].

Lack of Comprehensive Data

Despite its growing popularity, there remains a notable dearth of comprehensive data concerning the pharmacological properties, metabolism, and toxicity associated with 3-MeO-PCE. Its history of human usage is relatively brief, leaving many aspects of its effects and risks unclear.

Importance of Harm Reduction Practices

Given the limited understanding of 3-MeO-PCE and its potential risks, it is strongly recommended that individuals exercise harm reduction practices if they choose to use this substance. This includes thorough research, dosage moderation, and seeking support from knowledgeable sources.

Unveiling the Chemistry of 3-MeO-PCE

Structural Overview

3-Methoxyeticyclidine (3-MeO-PCE), chemically known as N-Ethyl-1-(3-methoxyphenyl)cyclohexan-1-amine, belongs to the arylcyclohexylamine class of drugs. These compounds are characterized by their structures, which incorporate a cyclohexane ring bound to an aromatic ring alongside an amine group. Specifically, 3-MeO-PCE comprises a phenyl ring with a methoxy (CH3-O-) substituent at R3, attached to a cyclohexane ring. Additionally, it features an amino ethyl chain (-NCH2CH3) bound to the same carbon (R1) of the cyclohexanone ring. Unlike drugs such as DCK and ketamine, which contain an amino methyl chain, 3-MeO-PCE and its analog MXE incorporate an amino ethyl chain. While analogous to MXE, 3-MeO-PCE lacks an R2 substituted ketone and is homologous to 3-MeO-PCP but does not possess the additional carbons required to complete a piperidine ring.

Delving into Pharmacology

Mechanism of Action

3-MeO-PCE primarily functions as an NMDA receptor antagonist. NMDA receptors facilitate the transmission of electrical signals between neurons in the brain and spinal column. For these signals to pass, the receptor must be open. Dissociatives like 3-MeO-PCE obstruct NMDA receptors, effectively shutting them down. This blockade results in neuronal disconnection, leading to sensations of numbness, impaired movement, and often culminating in an experience known as the "k-hole."

Receptor Affinities

3-MeO-PCE exhibits notable Ki values for various receptors:

• NMDA receptor: 61 nM
• Dopamine transporter: 743 nM
• Histamine H2 receptor: 2097 nM
• Alpha-2A adrenergic receptor: 964 nM
• Serotonin transporter: 115 nM
• σ1 receptor: 4519 nM
• σ2 receptor: 525 nM [6]

Exploring Subjective Effects

3-MeO-PCE shares similarities with 3-MeO-PCP, albeit with a potentially heightened risk of inducing manic states, delusions, and even psychosis due to its greater euphoric stimulation and tendency towards compulsive redosing. However, its effects tend to converge with those of 3-MeO-PCP once a certain dose threshold is reached, leading to predominance of dissociative effects.

Moreover, it is often reported to be more stimulating and less sedating compared to other dissociatives like ketamine or MXE. Its profile suggests a potential higher affinity for dopamine or serotonin, distinguishing it from compounds such as O-PCE, MXP, and diphenidine.

Disclaimer: The effects mentioned above are based on the Subjective Effect Index (SEI), derived from anecdotal user reports and analyses by PsychonautWiki contributors. It's important to approach these findings with caution, as individual experiences may vary and higher doses may increase the likelihood of adverse effects, including addiction and severe health complications.

Navigating Dosage Guidelines for 3-MeO-PCE

Threshold Dosage

• Threshold: 1 mg

Light Dosage

• Light: 3 - 6 mg

Common Dosage

• Common: 6 - 12 mg

Strong Dosage

• Strong: 12 - 20 mg

Heavy Dosage

• Heavy: 20 mg and above

Heavy doses exceeding 20 mg carry the risk of inducing psychosis and mania. It is imperative to approach dosing with caution and adhere to harm reduction practices to mitigate potential adverse effects.

Exploring the Physical Effects of 3-MeO-PCE

Stimulation

• This drug elicits significant stimulation, distinguishing itself from other dissociatives like ketamine, MXE, or DCK. The stimulation it provides is notably clean and comfortable, resembling that of 3-MeO-PCP more closely than O-PCE.

Perception of Bodily Lightness

• Users may experience a sensation of bodily lightness.

Restless Legs

• Restlessness in the legs may occur.

Spontaneous Physical Sensations

• The body high induced by 3-MeO-PCE manifests as a motionless, constant, sharp, and all-encompassing euphoria, akin to nerve activation across the body. This sensation is reminiscent of both 3-MeO-PCP and O-PCE but diminishes at higher doses due to the compound's disconnecting and anesthetic effects.

Physical Euphoria

• At lower to moderate doses, users may experience feelings of physical comfort, warmth, and euphoria spreading throughout the body. However, at heavier doses, this sensation may become neutral or potentially uncomfortable.

Bodily Control Enhancement

• Lower doses of 3-MeO-PCE typically enhance bodily control, but at higher doses, this enhancement transitions into losses in gross and fine motor control.

Tactile Enhancement & Tactile Suppression

• Lower doses may induce tactile enhancements, but at higher doses, these enhancements shift towards tactile suppression and anesthesia.

Motor Control Loss

• Similar to bodily control enhancement, lower doses may enhance motor control, while higher doses lead to losses in gross and fine motor control.

Changes in Felt Gravity

• Users may experience alterations in their perception of gravity.

Appetite Suppression

• The drug may suppress appetite.

Nausea Suppression

• Users may experience a reduction in nausea.

Pain Relief

• Analgesic effects may be present.

Increased Blood Pressure

• Higher doses may lead to increased blood pressure.

Increased Heart Rate

• Uncomfortably elevated heart rate may occur at heavier doses, particularly towards the trip's offset, reported to be more pronounced than with other dissociatives.

Respiratory Depression

• Respiratory depression may occur at heavier dosage levels.

Physical Autonomy

• Users may feel a sense of physical autonomy.

Olfactory Hallucinations

• Hallucinations related to smell may manifest.

Optical Sliding

• Visual distortions may result in optical sliding effects.

Spatial Disorientation

• Users may experience disorientation in spatial perception.

Dizziness

• Dizziness may occur during the experience.

Increased Perspiration

• Users may experience heightened perspiration.

Dehydration

• Dehydration may occur, necessitating adequate fluid intake.

Difficulty Urinating

• Difficulty urinating may be experienced.

Seizure

• Seizure activity has been reported, particularly at higher doses.

Investigating Disconnective Effects

Tactile Disconnection

• Users may experience a disconnection from tactile sensations.

Visual Disconnection

• Visual disconnection may lead to experiences akin to the "k-hole," characterized by holes, spaces, and voids alongside structures.

Consciousness Disconnection

• Disconnection from consciousness may occur.

Auditory Effects

Suppression

• Auditory suppression may occur.

Distortions

• Auditory distortions may be present.

Hallucinations

• Auditory hallucinations may manifest.

Multi-sensory Effects

Synaesthesia

• Users may experience synaesthetic phenomena.

Transpersonal Effects

Unity and Interconnectedness

• Transpersonal experiences of unity and interconnectedness may occur.

Unraveling the Cognitive Effects of 3-MeO-PCE

Anxiety Suppression

• 3-MeO-PCE may lead to a reduction in anxiety levels.

Disinhibition

• Users may experience a decrease in inhibitions.

Mania

• This effect is notably more common with 3-MeO-PCE compared to most other dissociatives. It often occurs during the trip's offset but can also manifest during the onset and come up phases.

Cognitive Euphoria

• The drug may induce feelings of cognitive euphoria.

Depersonalization

• Depersonalization, characterized by feelings of detachment from oneself, may occur.

Derealization

• Derealization, involving a sense of detachment from one's surroundings, may be experienced.

Delusion

• Delusional thinking is reportedly more common with 3-MeO-PCE compared to other dissociatives.

Delusions of Sobriety

• Users may experience false beliefs regarding their sobriety state.

Compulsive Redosing

• Compulsive redosing may be more prominent depending on the route of administration. For instance, it is particularly prevalent when smoked or vaporized due to the substance's rapid onset and offset.

Conceptual Thinking

• Users may experience enhanced conceptual thinking.

Creativity Enhancement

• The drug may enhance creativity.

Déjà Vu

• Experiences of déjà vu may occur.

Memory Suppression

• Memory suppression may be observed.

Ego Death

• The concept of ego death, involving a loss of the sense of self, may be experienced.

Amnesia

• Amnesia, characterized by memory loss, may occur.

Immersion Enhancement

• Users may feel a heightened sense of immersion in their experiences.

Increased Music Appreciation

• Music appreciation may be enhanced.

Analysis Suppression

• Suppression of analytical thinking processes may occur.

Introspection

• Users may engage in deep introspective thought.

Time Distortion

• Perceptions of time may be distorted.

Thought Deceleration

• Cognitive processes may slow down.

Psychosis

• Psychotic experiences are reportedly more common with 3-MeO-PCE compared to many other dissociatives.

Investigating Visual Effects

Enhancements

• Visual acuity may be enhanced, particularly at lower dosages.

Suppressions

• The drug may suppress aspects of visual perception, such as double vision and pattern recognition.

Distortions

• Visual distortions may include environmental cubism, perspective distortions, and scenery slicing.

Geometry

• Visual geometry induced by 3-MeO-PCE tends to be dark and simplistic compared to other dissociatives. It is characterized by interlocking lines and lacks intricate detail beyond level 4.

Hallucinatory States

Internal Hallucination

• Users may experience vivid internal hallucinations, including autonomous entities, landscapes, and scenarios.

Assessing Toxicity and Harm Potential

Lack of Scientific Study

• The toxicity and long-term health effects of recreational 3-MeO-PCE use have not been scientifically studied, and the exact toxic dosage remains unknown due to its limited history of human usage.

Psychosis

• 3-MeO-PCE has been associated with a higher incidence of psychosis, delusions, and mania compared to other dissociatives such as ketamine, diphenidine, or MXE. Numerous online reports describe serious consequences, including psychotic delirium and amnesia, after abusing the substance.

Harm Reduction Practices

• Extreme caution and harm reduction practices are strongly recommended when using 3-MeO-PCE:
  • Users should avoid consecutive days of use or developing addiction, as this increases the risk of severe adverse effects.
  • Dosage should not exceed recommended ranges, and users should start with extremely low doses and titrate up slowly.
  • Volumetric liquid dosing is advised due to the substance's potency.
  • Compulsive redosing before sobering up should be avoided.
  • Combining 3-MeO-PCE with other substances, especially stimulants, psychedelics, or other dissociatives, is not recommended due to the risk of psychosis.

Tolerance and Addiction Potential

• Chronic use of 3-MeO-PCE can lead to addiction and is associated with a high potential for adverse side effects, including psychosis. Reports suggest it may be more habit-forming than other dissociatives such as MXE, diphenidine, ephenidine, and ketamine.

Urinary Tract Effects

• Repeated and excessive use of 3-MeO-PCE may lead to bladder and urinary tract problems similar to those associated with ketamine, albeit to a lesser extent.

Dangerous Interactions

Warning

• Combining 3-MeO-PCE with certain substances can be dangerous or life-threatening:
  • Psychedelics: Due to the risk of extreme psychological disturbances such as psychosis and mania.
  • Stimulants: Increases the risk of adverse psychological reactions like anxiety, mania, delusions, and psychosis.
  • Depressants: Combination can result in respiratory depression and suffocation.

Legal Status

Germany

• Controlled under the NpSG (New Psychoactive Substances Act) since July 18, 2019.

Switzerland

• Classified as a controlled substance under Verzeichnis E.

Turkey

• Classified as a drug and illegal to possess, produce, supply, or import.

United Kingdom

• Class B drug, illegal to possess, produce, supply, or import under the Misuse of Drugs Act. Covered by the arylcyclohexylamine generic clause.

Frequently Asked Questions (FAQ)

1. What is 3-MeO-PCE?

3-Methoxyeticyclidine (3-MeO-PCE) is a novel dissociative substance belonging to the arylcyclohexylamine class, known for its dissociative and hallucinogenic effects.

2. Is 3-MeO-PCE legal?

The legal status of 3-MeO-PCE varies by country. For example, it is a controlled substance in Germany and Switzerland, while in the United Kingdom, it is classified as a Class B drug.

3. What are the risks associated with 3-MeO-PCE use?

The use of 3-MeO-PCE carries potential risks such as psychosis, delusions, mania, and urinary tract problems. Chronic use can lead to addiction and tolerance.

4. How should 3-MeO-PCE be used safely?

It is strongly recommended to exercise extreme caution and harm reduction practices when using 3-MeO-PCE. This includes starting with low doses, avoiding consecutive days of use, and avoiding combining it with other substances.

5. Are there any interactions to be aware of?

Combining 3-MeO-PCE with certain substances, such as psychedelics, stimulants, or depressants, can be dangerous and even life-threatening. It is essential to conduct independent research to ensure safe consumption.

6. What should I do in case of adverse effects?

If you experience adverse effects from 3-MeO-PCE use, such as psychosis or urinary tract issues, it is crucial to seek medical help immediately and discontinue use of the substance.

7. How can I reduce the risk of urinary tract problems?

To minimize the risk of urinary tract problems associated with 3-MeO-PCE use, it is recommended to avoid using the substance daily or weekly and to limit overall usage consciously.

8. How long does it take for tolerance to reset?

Tolerance to 3-MeO-PCE develops with prolonged and repeated use, but it typically takes 3 to 7 days for tolerance to reduce by half and 1 to 2 weeks to return to baseline after cessation of use.

9. Can 3-MeO-PCE cause addiction?

Yes, chronic use of 3-MeO-PCE can lead to addiction, with cravings and withdrawal effects reported upon sudden cessation of use. It is essential to approach its use with caution and awareness of its addictive potential.